Abstract
Background and objectives
As the prevalence of some gynecological conditions depends on patient characteristics such as race/ethnicity, it is important to study therapies for these conditions in diverse populations. The study described in this article was conducted to investigate the safety, tolerability, and pharmacokinetics of vilaprisan, a selective progesterone receptor modulator, in Japanese women in Japan. It supplements two comparable studies that were conducted in healthy postmenopausal European and Chinese women, respectively.
Methods
In this exploratory randomized, placebo-controlled, double-blind, ascending-dose study, five groups of healthy postmenopausal Japanese women received vilaprisan as immediate-release tablets (1, 5, or 15 mg as a single dose or 1 or 5 mg/day for 28 days) or placebo tablets (single dosing: 8 subjects/dose step, thereof 2 subjects randomized to placebo; multiple dosing: 12 subjects/dose step, thereof 4 subjects randomized to placebo). Blood samples for pharmacokinetic profiles were collected over 14–19 days. Safety assessments were based on adverse event data, vital signs, electrocardiograms, clinical laboratory tests, and transvaginal ultrasound examinations.
Results
48 participants were randomized, treated, and analyzed. Vilaprisan was rapidly absorbed, reaching maximum plasma concentrations (Cmax) between 1 and 3 h post dose. Post maximum, plasma concentrations rapidly declined, indicating pronounced distribution into tissues. The exposure of vilaprisan increased roughly dose-proportionally: The geometric mean (geometric coefficients of variation) areas under the concentration time curves from time zero to infinity (AUC∞) after single administration of 1, 5, or 15 mg vilaprisan were 67 µg·h/l (34%), 249 µg·h/l (15%), and 788 µg·h/l (37%), respectively. The AUC in the dosing interval after multiple administrations (AUC24,md) of 1 mg/day was 76 µg·h/l (59%), and the AUC24,md after 5 mg/day was 311 µg·h/l (20%). Geometric mean Cmax values also increased roughly dose-proportionally: They amounted to 6 µg/l (22%), 16 µg/l (33%), and 52 µg/l (27%) after single administration and to 8 µg/l (28%) and 31 µg/l (22%) after multiple administrations of the above doses. Mild adverse events were observed, similar to those observed in other clinical studies of vilaprisan.
Conclusions
Overall, vilaprisan was safe and well tolerated. The exposure in Japanese women was similar to that observed in European and Chinese women in separate studies.
Trial Registration
15 Nov 2011 (no registration number assigned).
Similar content being viewed by others
References
Wagenfeld A, Bone W, Schwede W, Fritsch M, Fischer OM, Moeller C. BAY 1002670: a novel, highly potent and selective progesterone receptor modulator for gynaecological therapies. Hum Reprod. 2013;28:2253–64. https://doi.org/10.1093/humrep/det247.
Schultze-Mosgau M-H, Schuett B, Hafner F-T, Zollmann F, Kaiser A, Hoechel J, Rohde B. Pharmacokinetics and safety of the selective progesterone receptor modulator vilaprisan in healthy postmenopausal women. Int J Clin Pharmacol Ther. 2017;55:16–24. https://doi.org/10.5414/CP202756.
Schultze-Mosgau M-H, Höchel J, Prien O, Zimmermann T, Brooks A, Bush J, Rottmann A. Characterization of the pharmacokinetics of vilaprisan: bioavailability, excretion, biotransformation, and drug–drug interaction potential. Clin Pharmacokinet. 2018;57:1001–15. https://doi.org/10.1007/s40262-017-0607-4.
Chattopadhyay N, Kanacher T, Casjens M, Frechen S, Ligges S, Zimmermann T, et al. CYP3A4-mediated effects of rifampicin on the pharmacokinetics of vilaprisan and its UGT1A1-mediated effects on bilirubin glucuronidation in humans. Br J Clin Pharmacol. 2018;84:2857–66. https://doi.org/10.1111/bcp.13750.
Liu H, Jiang J, Chen Z, Zhang Y, Li J, Hoechel J, et al. Pharmacokinetics and safety of the selective progesterone receptor modulator vilaprisan in Chinese healthy postmenopausal women. Clin Pharmacol Drug Dev. 2020. https://doi.org/10.1002/cpdd.851.
US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Bioanalytical Method Validation. Guidance for Industry. Final guidance document. May 2018. Biopharmaceutics. 2018. https://www.fda.gov/media/70858/download. Accessed 8 May 2020.
European Medicines Agency (EMA). Committee for medicinal products for human use (CHMP): guideline on bioanalytical method validation. EMEA/CHMP/EWP/192217/2009 Rev. 1 Corr. 2. London, 21 July 2011. 2011. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-bioanalytical-method-validation_en.pdf. Accessed 8 May 2020.
Schultze-Mosgau M-H, Ploeger BA, Frei M, Rottmann A. Clinical pharmacokinetics and pharmacodynamics of the selective progesterone receptor modulator vilaprisan: a comprehensive overview. Clin Pharmacokinet. 2021. https://doi.org/10.1007/s40262-021-01073-3.
Sutter G, Frei M, Schultze-Mosgau M-H, Petersdorf K, Seitz C, Ploeger B. Assessment of the safe and efficacious dose of the selective progesterone receptor modulator vilaprisan for the treatment of patients with uterine fibroids by exposure-response modelling and simulation. Br J Clin Pharmacol. 2021. https://doi.org/10.1111/bcp.15014.
Stewart EA, Cookson CL, Gandolfo RA, Schulze-Rath R. Epidemiology of uterine fibroids: a systematic review. BCOG. 2017;124:1501–12. https://doi.org/10.1111/1471-0528.14640.
Acknowledgements
The authors would like to thank Barbara Schütt for her medical expert support in the planning of the clinical study and evaluation of the study results and Ercan Sükür, Bayer AG, Berlin, Germany, for preparing the graphs. Medical writing support was provided by C. Hilka Wauschkuhn, Bonn, Germany, on behalf of Bayer AG.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
The study was sponsored by Bayer AG, Germany.
Conflict of interest
All authors except SM are or were employees of Bayer AG. SM was an employee of the Kyushu Clinical Pharmacology Research Clinic, Fukuoka, Japan, where the study was conducted on behalf of Bayer AG.
Ethical approval
This study was performed in line with the principles of the Declaration of Helsinki. The protocol for this study was approved by the relevant independent ethics committee, the Kyushu Clinical Pharmacology Research Clinic IRB, Fukuoka, Japan, before the start of the study.
Consent to participate
All subjects gave their written informed consent before entry into the study.
Consent for publication
Not applicable.
Code availability
Not applicable.
Availability of data and material
The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.
Author contributions
All authors contributed to the study conception and design and/or the analysis and interpretation of the data. MSM prepared the first draft of the manuscript. All authors commented on this version and later versions. All authors read and approved the final manuscript. SM was the principal investigator of the study.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Schultze-Mosgau, MH., Matsuki, S., Okumura, K. et al. Single- and Multiple-Dose Pharmacokinetics and Safety of Vilaprisan in Healthy Postmenopausal Japanese Women: A Randomized Clinical Trial. Eur J Drug Metab Pharmacokinet 47, 49–56 (2022). https://doi.org/10.1007/s13318-021-00727-8
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13318-021-00727-8